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access and uptake of novel oncology drugs in the Slovak repub-
lic over a 7 year period based on sales data provided by IMS
Health. Slovakia has a national public oncology register, which
collects incidence, mortality and stage of diagnosis on all cancer
types. We linked the national cancer epidemiological data to
the cancer drug list and to the sales for cancer drugs. We per-
formed analysis of the possible effect of novel cancer drug
introduction and consumption on cancer survival and mortal-
ity. RESULTS: Oncological disease mortality in Slovakia had an
increasing trend on a long-term basis, from 1999–2000 the
mortality has decreased. Incidence and prevalence (in accor-
dance with the world trends) increases. According to IMS and
OECD health data the market for L01 and L02 drugs was
€53,593 000, this represents €10 per inhabitant. Expenditures
in L01 + L02 accounts for 8,9% of the Rx expenditures or
7,9% of Total Pharma Market. CONCLUSIONS: Patient
access to new cancer drugs in Slovakia improved signiﬁcantly in
the last years. It is highly probable that the improving survival
is related to the use of modern surgical and diagnostic methods,
earlier diagnostics of oncological diseases and better availability
of innovative drugs.
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OBJECTIVES: Public health approaches for prevention are con-
sidered to be successful with climbs in the numbers of services
rendered. However, more thorough evaluations are required to
uncover the still unmet need that remains hidden and harder to
reach. The objective of this study is to estimate the impact of
physician supply, mammography facilities, and managed care
penetration on use of mammography screening. METHODS:
Retrospective self-reported cross-sectional data from Behavioral
Risk Factor Surveillance System for years 2000, 2002, and 2004
along with county level supply variables from area resource ﬁle,
were used in the analysis. The analysis was restricted to females
between 40–69 years of age. We estimate a series of multivariate
regression model to assess the effect of individual and contextual
supply variables on mammography screening. We also use varia-
tion in the physician supply, managed care penetration at the
county level over the 5-year period to estimate its impact on
mammography screening using a ﬁxed effect estimation
approach. RESULTS: Women living in rural areas were less likely
(Coefﬁcient = -0.023, 95% CI = -0.031–0.014) to obtain a
mammogram even after controlling for supply side variable .
Among the supply side variables only managed care penetration
signiﬁcantly predicted mammography screening. In areas with
higher managed care penetration, women were more likely to get
screened. CONCLUSIONS: Insurance status was one of the
major determinants of mammography screening for females
residing in rural areas. Contextual supply variables had lesser
impact on mammography screening compared to individual level
characteristics.
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OBJECTIVES: To evaluatie simultaneously frequency of occur-
rence, outcomes, and cost of care of renal cell carcinoma (RCC),
in order to provide empiric evidence on the burden of RCC.
METHODS: Retrospective, naturalistic longitudinal study based
on claims of individuals enrolled in the Friuli Venezia Giulia
(FVG) administrative database. Since 1980, all FVG inhabitants
are registered in an administrative database which includes infor-
mation on hospital admissions, outpatients care, pharmaceutical
prescriptions and mortality. We selected residents of FVG who
had a RCC ﬁrst hospital admission (ICD9 code 189) during the
period 2000–2004, and we followed them up until: June 30,
2005, death or transfers. Direct medical costs (hospitalizations,
drugs, visits, diagnostics and laboratory exams) were quantiﬁed
using prices or tariffs expressed in Euro 2005. The perspective of
FVG Regional Health Service was adopted. Survival and costs
analysis were performed considering the presence or the absence
of metastases. RESULTS: We enrolled 1358 patients (63% male),
the 18.8% representing a metastatic-stage, leading to a crude
incidence of 23/100,000 person-years. During follow-up, 76% of
the metastatic patients and 21% of the non metastatic patients
died. The risk of death was signiﬁcantly higher among metastatic
stage patients with a median survival of about six months. The
cost per patient related to the ﬁrst year after diagnosis for sub-
jects with and without metastases was €13,692 and 10,502 Euro,
respectively, with a mean difference of 3,363 Euro after adjusting
for age and sex. Total health care costs per-patient over the
maximum of follow-up were €16,090 for the localized-stage
group and €17,656 in the metastatic-stage group. CONCLU-
SIONS: Results from our study show that, due to the large
number of hospitalizations and the high mortality, the epidemio-
logic and socioeconomic burden to the health care system and to
the society of RCC is high.
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OBJECTIVES: In order for a new pharmaceutical treatment to
demonstrate cost-effectiveness, it is important to understand the
current standard clinical management practices for the relevant
patient population. In some therapeutic areas, this information
can be readily gleaned from clinical practice guidelines, data-
base analyses and clinical input. However, in more complex
conditions, standard practices are undeﬁned and vary markedly
both within and between countries. In such circumstances,
valuable information can be obtained by conducting a chart
audit. We report on the different approaches and requirements
for conducting chart audits in Australian hospitals.
METHODS: In total, 79 potential investigators were invited to
participate in two separate studies. Investigators were contacted
up to four times to maximise response. 52 investigators
responded and 12 agreed to participate. Two investigators
agreed to participate in both studies. RESULTS: All sites
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required ethics approvals, yet the level of information required
varied considerably. Six of ten sites required the protocol, case
report form and an explanatory letter only. One of these sites
subsequently requested additional information resulting in a
delay of over two months. Another site allowed an expedited
review, but required supplementary forms totaling 42 pages.
Three sites required full ethics submissions. At six sites, a con-
tract was required, necessitating legal review and negotiation.
The remaining sites required a letter outlining the ﬁnancial
arrangements. The cost of the ethics processes ranged from
AU$500 to AU$3700. CONCLUSIONS: There is considerable
variability in the processes followed by Australian hospitals
when conducting chart audits which impacts on time and cost,
and must be taken into account when planning such a study.
Nevertheless, implementation of a well-planned chart audit
provides valuable information that will allow the development
of a strong cost-effectiveness argument.
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OBJECTIVES: Despite treatment advances, mCRC, the second-
leading cause of cancer-related deaths, imposes a substantial
burden to patients and public health. Panitumumab, a novel
therapeutic agent, is the ﬁrst fully human anti-EGFR mono-
clonal antibody and is currently approved as monotherapy for
patients expressing wild type (wt) KRAS, after failure of
ﬂuoropyrimidine-, oxaliplatin-, and irinotecan-containing che-
motherapy regimens. Panitumumab has introduced the concept
of individualised therapy in mCRC as it is indicated for patients
with speciﬁc KRAS gene, wt KRAS. This study evaluated the
overall budget impact (BI) of panitumumab on the total health
care budget in mCRC management in Greece. METHODS: A
decision analytic model estimating the cost associated with pani-
tumumab treatment and Best Supportive Care (BSC) was devel-
oped for the assessment of the BI for the Greek health care
system. Treatment costs included primary drug costs, infusion
costs, concomitant medications, clinic visits, hospitalisations and
radiation therapy. In the absence of local cancer registry, an
expert panel was used to map mCRC patient ﬂow. The cost
calculations were separately carried out for public and private
sectors. RESULTS: Out of 470 potentially eligible patients for
panitumumab monotherapy, the decision analytic model targets
268 (57%) patients with wt KRAS, according to the indication.
Panitumumab was calculated in addition to BSC. In the public
setting, the total panitumumab cohort budget was €4.8 million
and the average cost/patient treated €17,998. In the private
setting, the total panitumumab cohort budget was €5 and the
average cost/patient treated €18,716. CONCLUSIONS: Panitu-
mumab improves treatment outcomes and reduces unnecessary
exposure to therapy, with a modest health care budget impact. By
identifying the population of wt KRAS patients who are most
likely to beneﬁt, panitumumab increases patient-level clinical
outcomes and may lead to the rational use of health care
resources in Greece.
PCN105
MEDICARE PART D’S MARKET IMPACT ON UTILIZATION,
AVERAGE RETAIL PRICE AND OUT-OF-POCKET SPENDING
FOR ORAL CHEMOTHERAPEUTICS AND A COMPARATIVE
MARKET BASKET OF DRUGS
Horowicz-Mehler N, Sepulveda B, Doyle JJ
Quintiles Global Consulting, Hawthorne, NY, USA
OBJECTIVES: To determine whether Medicare Part D coverage
of prescription oral chemotherapeutics and a comparative
market basket of non-oncologics impacted trends in prescrip-
tion volume, retail price, and out-of-pocket costs. To assess
these trends over the 2005–2008 period, including the January
1, 2006 implementation of Medicare Part D. To investigate
geographic trends for states with and without major accredited
cancer centers (MACCs). METHODS: The top ﬁve prescribed
oral chemotherapeutics (capecitabine, imatinib, temozolomide,
chlorambucil, cyclophosphamide) and a comparative market
basket consisting of the top two prescribed anticonvulsants
(clonazepam, gabapentin), antidepressants (escitaprolam, ﬂuox-
etine), antipsychotics (quetiapine, risperidone), HIV/AIDS
(emtricitabine/tenofovir, ritonavir) and immunosuppressants
(azathioprine, mycophenolate) were selected based on total pre-
scriptions (TRx) between January 2005 and April 2008. For
that time frame, TRx, average retail price (ARP) and out-of-
pocket costs (OPC) per prescription for both Medicare Part D
patient and non-Part D Medicare patients were collected.
Finally, average TRx and ARP were compared in MACC states
versus non-MACC states over that time. Parameters were col-
lected using the Verispan’s VONA and VOPA databases. Sta-
tistical analyses were performed using one-way ANOVA.
RESULTS: Quarterly imatinib TRx increased signiﬁcantly more
than the other chemotherapeutics, >30% between Q1 2005 and
Q1 2008 (p < 0.05). This increase was mostly attributable to an
increase in reﬁlls, which was signiﬁcantly greater than the other
chemotherapeutics (p < 0.05). Interestingly, average TRx were
signiﬁcantly higher in MACC states (p < 0.05). The ARP sig-
niﬁcantly increased for capecitabine, imatinib and temozolo-
mide (33% average), while half of the comparative market
basket drugs saw an increase in ARP (30% average increase for
those 6; p < 0.05). With the exception of imatinib, the average
OPC was signiﬁcantly less for Medicare Part D patients than
for non-Part D patients (p < 0.05). Nonetheless, over time, the
OPC only increased signiﬁcantly for capecitabine and for two
of the market basket drugs (p < 0.05). CONCLUSIONS: The
introduction of Medicare Part D did not appear to impact ARP
or utilization for the top oral chemotherapeutics. One possible
explanation is Medicare Part B coverage of certain oral chemo-
therapeutics prior to January 1, 2006. Secondly, there may be
some drug classes that are more sensitive than others to
changes in health care policy. We observed a positive correla-
tion between MACC designation with utilization and ARP
patterns.
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OBJECTIVES: Determine how prostate cancer (PC) is diagnosed
in Spain as well as its economical impact on NHS budget.
METHODS: Cross sectional multicenter study conducted in
urology and specialized units in Spain during 2006. Information,
retrospectively compiled, from >18 years, 3 months—2 years
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